Sort   by:  
 Page size 
MetabolomicsCell of origin epigenetic priming determines susceptibility to Tet2 mutation

Hematopoietic stem cell (HSC) mutations can result in clonal hematopoiesis (CH) with heterogeneous clinical outcomes. Here, we investigated how the cell state preceding Tet2 mutation impacts the pre-malignant phenotype. Using an inducible system for clonal analysis of myeloid progenitors...

2024-04-30 | MTBLS9914 | MetaboLights
MetabolomicsMetabolomic profiling of cerebrospinal fluid from dogs with meningoencephalitis of unknown origin by nuclear magnetic resonance

Introduction: Meningoencephalitis of unknown origin (MUO) in dogs is a very debilitating and potentially fatal disease that is a potential model for multiple sclerosis in humans. The metabolomic profile of MUO has not been previously reported.

Objectives: To describe the metabolomic profile...

2026-03-05 | MTBLS6053 | MetaboLights
GenomicsUnraveling cell type–specific and reprogrammable human replication origin signatures associated with G-quadruplex consensus motifs
Short nascent strands purification coupled to next-generation sequencing allowed us to identify replication origins on human genome in an extensive way, by mapping replication origins in 4 different cell types, IMR-90 fibroblasts, hESC H9 cells, iPSC Th Cl-4 cells and HeLa cells. We demonstrated the...
ORGANISM(S): Homo sapiens 
2012-07-01 | E-GEOD-37757 | biostudies-arrayexpress
MetabolomicsCurcumin (analogue) metabolites in intestinal cell lines
Curcumin and curcumin-based benzothiazepane analogues were investigated in intestinal cell lines of cancer (HCT-116) and non-cancer (IPEC-J2) origin. After 0h, 3h and 15h incubation, the cell lysates and extracellular media were analysed using LC-QTOF-MS.
2026-07-20 | MTBLS15099 | MetaboLights
MetabolomicsCoupled Mass-Spectrometry-Based Lipidomics Machine Learning Approach for Early Detection of Clear Cell Renal Cell Carcinoma

A discovery-based lipid profiling study of serum samples from a cohort that included patients with clear cell Renal Cell Carcinoma (ccRCC) stage I, II, III, and IV (n=112) and controls (n=52) was performed using ultraperformance liquid chromatography coupled to quadrupole-time-of-flight mass spec...

2020-11-20 | MTBLS1839 | MetaboLights
MetabolomicsLipidomic analysis of Toxoplasma gondii extracellular vesicles across host cell types

Introduction. Toxoplasma gondii is an obligate intracellular parasite with an exceptional capacity to colonize a broad range of host species and cell types. Successful infection depends on its ability to manipulate host metabolism, including lipid pathways that are essential for membrane biogenes...

2026-02-11 | MTBLS13253 | MetaboLights
MetabolomicsMulti-omics Analysis of ACAD11-mediated Lipid Metabolic Reprogramming in the Prognosis of Clear Cell Renal Cell
Clear cell renal cell carcinoma (ccRCC) is pathologically characterized by profound intracellular lipid droplet accumulation. To explore the dysregulated lipid metabolic network and identify crucial drivers, an integrated transcriptomic and untargeted metabolomic analysis was conducted. In this stud...
2026-08-31 | MTBLS15414 | MetaboLights
MetabolomicsCell overgrowth potentiates osmotic and replication stresses to promote p38/p53/p21-dependent senescence
Abnormal increases in cell size are associated with senescence and cell cycle exit. The mechanisms by which overgrowth primes cells to withdraw from the cell cycle remain unknown. We address this question using CDK4/6 inhibitors, which arrest cells in G0/G1 and are licensed to treat advanced HR+/HER...
2025-10-24 | MTBLS8698 | MetaboLights
MetabolomicsA polyamine-centric blood-based metabolite panel predictive of poor response to CAR T-cell therapy in large B cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (r/r) large B-cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to treatment. We tested whether a MYC-driven polyamin...

2022-10-31 | MTBLS5381 | MetaboLights
MetabolomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistance to PARPi poses a significant challenge for long-term efficacy of these therapies, warranting further understanding of mechanisms of...
2026-05-11 | MTBLS12109 | MetaboLights
Sort   by:  
 Page size